Journal of Allergy and Clinical Immunology-In Practice最新文献

{"title":"Targeting IL-4/IL-13, IL-5 or IgE axes in chronic rhinosinusitis with nasal polyps with and without sinus surgery: a network meta-analysis.","authors":"José Laerte Boechat, Bernardo Sousa-Pinto, Luís Delgado, Diana Silva","doi":"10.1016/j.jaip.2025.06.013","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.013","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baked-Milk Modulates Cow's Milk Allergy in Children: Impact of Phenotype, Age, Intake.","authors":"O Domínguez, E Poyatos, C Riggioni, G Salamanca, R M Jiménez-Feijoo, J LozanoMD, M Piquer, A Machinena, M Folqué, I Ortiz de Landazuri, M Lasa, L Alsina, M Pascal, M Alvaro-Lozano","doi":"10.1016/j.jaip.2025.06.011","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.011","url":null,"abstract":"<p><strong>Background: </strong>Limited evidence indicates that baked milk (BM) intake accelerates cow's milk allergy (CMA) resolution or modulates immunity in baked milk-tolerant (BMT) and baked milk-allergic (BMA) phenotypes.</p><p><strong>Objective: </strong>This study evaluates the efficacy, safety, and immunological effects of BM introduction, focusing on regular intake in BMT and low-dose intake in BMA, and their impact on tolerance development.</p><p><strong>Methods: </strong>A prospective study including children 12-72 months of age with oral food challenge (OFC) confirmed CMA. CMA children were categorized into BMT or BMA phenotypes based on BM-OFC results. BMT children were randomized into two groups: B2 (daily intake of 0.55 g BM-protein (BMP) and C2 (strict avoidance of BM). BMA children who tolerated the minimal dose were similarly randomized: B1 (daily intake of 0.0375 g BMP) and C1 (strict avoidance of BM). Assessments at baseline (T0) and 12 months (T1) included skin prick tests (SPT), specific-IgE (sIgE), specific-IgG4 (sIgG4), basophil activation test (BAT), and T-cell cytokine profile. BM doses doubled at six months, and CM-OFC confirmed outcomes at T1.</p><p><strong>Results: </strong>A total of 50 participants with confirmed CMA were included, of whom 32 were BMT and 18 BMA. Daily BM intake in the B2 group significantly enhanced tolerance to CM (77.2% vs 40% in C2, p < 0.05), with improved safety and marked reductions in SPT and sIgE markers. Reactivity thresholds increased ninefold (0.9 g vs 0.05 g). No significant increase in tolerance was seen in the B1 group. Mild home reactions occurred in 9.3%. Predictors of tolerance included early age (<24 months), BM consumption, absence of asthma, immunological markers (sIgE, SPT, sIgG4/sIgE), and reduced BAT reactivity.</p><p><strong>Conclusions: </strong>Early BM introduction appears to support CMA resolution in BMT and may enhance safety, particularly in young children. Regular BM consumption could contribute to better outcomes, while biomarkers offer valuable insights for personalized management.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Mepolizumab Use in Chronic Spontaneous Urticaria: An Open-Label, Single-Arm, Exploratory Study.","authors":"Jordan Phillipps, Arveen Bhasin, Jason Sluzevich","doi":"10.1016/j.jaip.2025.06.014","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.014","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid rise in unspecified mast cell activation diagnosis code usage in the United States.","authors":"Stefani Aleman, Ollie Anna Bystricky, Dominique Denbow, Mildred Kwan, Evan S Dellon, Onyinye I Iweala","doi":"10.1016/j.jaip.2025.06.009","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.009","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TIME COURSE UNTIL TOLERANCE FOR FOOD PROTEIN-INDUCED ALLERGIC PROCTOCOLITIS VARIES BY THE CAUSAL FOOD.","authors":"Nagihan Iskender, Nefise Nezihe Uluç, Ismail Ozanli, Belkis Ipekci, Taha Yasin Akın, Mujde Tuba Cogurlu","doi":"10.1016/j.jaip.2025.06.010","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.010","url":null,"abstract":"<p><strong>Background: </strong>For food protein-induced allergic proctocolitis (FPIAP) published information on the time until tolerance for each causal food and their combinations remain scarce.</p><p><strong>Objective: </strong>To determine time until tolerance for individual causal foods, causal foods in combination, and factors affecting tolerance development.</p><p><strong>Methods: </strong>Out of the 91 patients diagnosed with FPIAP between March 2019-March 2020, 84 patients with at least three years of follow-up were evaluated in this prospective cohort.</p><p><strong>Results: </strong>The median age was 50 months at last evaluation (interquartile range [IQR]: 47-54) and 52.4% were male. The tolerance development rate was 36.6% in the first year, 88.9% in the second year, 96.4% in the third year, and 97.6% after the age of 3 years. Overall median tolerance development time was 15.5 (IQR: 12-22.5) months. For each causal food, cow's milk (CM), beef, wheat, eggs, and nuts, median times until tolerance were 13 (IQR: 12-18), 13 (IQR: 12-18), 14 (IQR: 10.7-16), 16 (IQR: 12-24), and 24 (IQR: 22.5-36.5) months, respectively. In multiple food allergies (MFA), the presence of eggs significantly prolonged the time until tolerance, whereas presence of beef did not. Multivariate regression analysis revealed that MFA presence (odds ratio [OR]: 12.11, 95% confidence interval [CI]: 1.23-118.12, p=0.03), atopic dermatitis (AD) at onset (OR: 4.04, 95% CI: 1.15-14.25, p=0.03), and the absence of a pet at home (OR: 0.23, 95% CI: 0.06-0.87, p=0.03) were associated with delayed tolerance. The presence of IgE-mediated food allergy at onset was also associated with delayed tolerance (p=0.02).</p><p><strong>Conclusion: </strong>Tolerance development times to egg and nuts were longer than to CM, beef, and wheat in FPIAP. Delayed tolerance appears to be due to the specific food combinations rather than multiple foods.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compassionomics: Translating Evidence-Informed Patient-Centered Care To The Allergy Immunology Clinic.","authors":"Don Bukstein, Alan P Baptist, Alexandra E Conway, Marylee Verdi, Aikaterini Anagnostou, Elissa M Abrams, S Shahzad Mustafa, John Oppenheimer, David M Lang, Jason Sanders, Julia Upton, Allison Hicks, Marcus Shaker","doi":"10.1016/j.jaip.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.003","url":null,"abstract":"<p><p>The quadruple aim of healthcare is to improve the healthcare experience for patients, populations, and clinicians while also controlling healthcare costs. Evidence-based and evidence-informed medicine is critical in achieving these goals. However, the receipt and acceptance of evidence-based medicine is maximized (and often only possible) when accompanied by compassion. Expressing compassion can be communicated through four central themes: acknowledgement, partnership, empowerment, and commitment. \"Compassionomics\" refers to the value of compassion in achieving the quadruple aim of healthcare, wherein genuine human connection between patient and clinician is the currency which 'opens the door' so that evidence-based medicine can be implemented, often in a shared decision-making capacity. Although difficult to quantify and often perceived as time-consuming, compassionate care improves the efficacy of healthcare interactions, likely saving time and improving long-term outcomes. While compassion comes naturally to some individuals, it is nevertheless a skill that can be taught and refined. Implementation of compassionomics into clinical care can be challenging, although implementation sciences offers novel approaches to make this possible.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and diagnostic features in 18 patients with Vibratory Urticaria: is Uvular Edema a distinct entity?","authors":"Carolina Gómez Fariñas, Manuel Rial Prado, Olinda Pérez-Quintero, Antonio Parra Arrondo, Beatriz Veleiro Pérez","doi":"10.1016/j.jaip.2025.06.001","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.06.001","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel approach to consider Planetary Health in guideline development: a GRADE approach using the Allergic Rhinitis and its Impact on Asthma (ARIA) 2024-2025 guidelines as a case-study.","authors":"Rafael José Vieira, Bernardo Sousa-Pinto, Alina Herrmann, Josep Antó, Sian Williams, Antonio Bognanni, Ana Margarida Pereira, Tari Haahtela, Grigorios I Leontiadis, Oliver Pfaar, Arunas Valiulis, Torsten Zuberbier, Thomas Piggott, Holger J Schünemann, Jean Bousquet","doi":"10.1016/j.jaip.2025.04.060","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.04.060","url":null,"abstract":"<p><p>The concept of planetary health emphasizes the inherent connection between the health of humans and the health of the planet, on which human health depends. The planetary boundaries framework describes nine planetary life support systems, including climate change and biodiversity, and defines a safer operating space for humanity. The healthcare sector, while striving to improve human health, contributes significantly to exceeding those planetary boundaries, for instance through greenhouse gas emissions, water use, and waste generation. The integration of Planetary Health considerations into health guidelines is, therefore, essential to achieve a delicate sustainable balance between improving individual human health and minimizing planetary health impacts. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group is developing guidance for incorporating Planetary Health into the health guideline development process. In this paper, we address the need for evidence to support planetary health considerations in allergic disease guidelines. In addition, we review sources of evidence, such as lifecycle assessment studies, which provide evidence about the environmental impacts of medical products over the full lifecycle from production to disposal. Finally, we present the 2024-2025 Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines as an example of how to account for Planetary Health when direct quantitative evidence is limited., showcasing how Planetary Health considerations were embedded into the guideline development process through a dedicated criterion in the Evidence-to-Decision framework.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Mortality Indicate Sex Differences in Chronic Rhinosinusitis with Nasal Polyposis.","authors":"Michael D'Netto, Alex iAkushev, Phillip Link, Kelley Dages, Benjamin Hamel, Jenny Patel, Nisha Patel, John Hagan, Thanai Pongdee, James Li, Joseph Butterfield, Gerald Volcheck, Miguel Park, Avni Joshi, Chien-Chang Chen, Sydney Pulsipher, Rohit Divekar, Sergio E Chiarella, Scott Harmsen, Elina Jerschow","doi":"10.1016/j.jaip.2025.05.061","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.05.061","url":null,"abstract":"","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk for Angioedema with the Use of Dipeptidyl Peptidase 4 Inhibitors: A Population-Based Cohort Study.","authors":"Bin Hong, Hyesung Lee, Jae Hyun Bae, Young Min Cho, Ju-Young Shin","doi":"10.1016/j.jaip.2025.05.060","DOIUrl":"https://doi.org/10.1016/j.jaip.2025.05.060","url":null,"abstract":"<p><strong>Background: </strong>Dipeptidyl peptidase 4 (DPP4) inhibitors, which are widely used antidiabetic medications, may induce the accumulation of bradykinin and substance P, and thus possibly increase the risk for angioedema.</p><p><strong>Objective: </strong>To assess the risk for angioedema with the use of DPP4 inhibitors compared with other second-line oral antidiabetics (OADs) in patients with type 2 diabetes (T2D).</p><p><strong>Methods: </strong>A cohort study was conducted using a nationwide healthcare data of South Korea (2010-2022). Patients aged over 40, with T2D, initiating DPP4 inhibitors or other second-line OADs were included. The primary outcome was angioedema, and the secondary outcome was serious angioedema. Hazard ratio (HR) and rate difference (RD) per 1000 person-years between DPP4 inhibitors and other OADs were estimated within a 1:1 propensity score-matched cohort.</p><p><strong>Results: </strong>This study included 1 410 173 patients initiating DPP4 inhibitors and 966 137 patients initiating other second-line OADs, 99.1% of whom were not using concomitant angiotensin-converting enzyme (ACE) inhibitor due to prescription patterns in South Korea. Over a 1.5-year mean follow-up, no difference in the risk for angioedema with the use of DPP4 inhibitors versus OADs was observed (0.47 and 0.48 events per 1000 person-years, respectively), with an HR of 0.99 [95% CI, 0.89 to 1.12] and a RD of -0.01 [95% CI, -0.07 to 0.05] per 1000 person-years, respectively. The risk for serious angioedema did not increase (RD, -0.001 [95% CI, -0.006 to 0.004]; HR, 0.73 [95% CI, 0.15 to 3.65].</p><p><strong>Conclusions: </strong>In this large cohort study, the use of DPP4 inhibitors, with 99.1% of users not on concomitant ACE inhibitor therapy, was not associated with an increased risk for angioedema compared with other second-line OADs. However, further studies are needed to determine this risk in those on ACE inhibitor treatment.</p>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}